Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIL-214
- Development stage
- Unknown
- Lead developer
- HilleVax
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
HIL-214 (formerly TAK-214) is a bivalent virus-like particle (VLP) vaccine candidate developed for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus. Originally developed by Takeda Pharmaceutical Company and later licensed to HilleVax, the vaccine consists of VLPs from two norovirus genotypes: GI.1 (Norwalk strain) and GII.4c (a consensus sequence derived from GII.4 variants). It is formulated with an aluminum hydroxide adjuvant and administered via intramuscular injection. The vaccine works by eliciting histo-blood group antigen (HBGA)-blocking antibodies, which interfere with the binding of the norovirus capsid to host cell receptors, thereby preventing viral entry and infection. Clinical development has progressed through Phase 2 trials in various age groups, including infants and adults.
- Other names
- GI.1/GII.4-Takeda-norovirus infectionNorovirus GI.1/GII.4 Bivalent VLP VaccineGI.1/GII.4 bivalent norovirus vaccine
02
Targets
GII.4 VP1 (Norovirus GII.4 VP1)GI.1 VP1 (Norovirus GI.1 VP1)
Beyond the preview
Go deeper on HIL-214.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIL-214.